Plain-English translation of NCT05963217 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is the first human study of , a new type of cell therapy designed to fight blood cancers that have come back or stopped responding to previous treatments. Researchers take your own immune cells, modify them in a lab to recognize and attack cancer cells, and then infuse them back into your body. The study will test different doses of this medication to find the right amount and see how well it works.
Many people with relapsed or hard-to-treat blood cancers like lymphoma and leukemia run out of effective treatment options. This new treatment takes a different approach by harnessing your own immune system, and early lab studies suggest it may be more effective than older versions of this therapy.
You likely qualify if…
You likely don't qualify if…
First, you would undergo a procedure to collect your own immune cells from your blood. You'll then receive chemotherapy to prepare your body for the new cells. About 2–3 weeks later, the modified cells that were grown in the lab will be infused back into you intravenously. After that, you'll have regular clinic visits for monitoring and blood tests. The study includes 5 years of follow-up to track how well the treatment works and any side effects. The exact number and timing of visits depends on which dose level you're assigned to.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
Canada